First Time Loading...

Nurix Therapeutics Inc
NASDAQ:NRIX

Watchlist Manager
Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc
NASDAQ:NRIX
Watchlist
Price: 12.02 USD -3.61% Market Closed
Updated: May 1, 2024

Intrinsic Value

NRIX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Nurix Therapeutics, Inc. is a biopharmaceutical company. [ Read More ]

The intrinsic value of one NRIX stock under the Base Case scenario is 29.65 USD. Compared to the current market price of 12.02 USD, Nurix Therapeutics Inc is Undervalued by 59%.

Key Points:
NRIX Intrinsic Value
Base Case
29.65 USD
Undervaluation 59%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Nurix Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NRIX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Nurix Therapeutics Inc

Provide an overview of the primary business activities
of Nurix Therapeutics Inc.

What unique competitive advantages
does Nurix Therapeutics Inc hold over its rivals?

What risks and challenges
does Nurix Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Nurix Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Nurix Therapeutics Inc.

Provide P/S
for Nurix Therapeutics Inc.

Provide P/E
for Nurix Therapeutics Inc.

Provide P/OCF
for Nurix Therapeutics Inc.

Provide P/FCFE
for Nurix Therapeutics Inc.

Provide P/B
for Nurix Therapeutics Inc.

Provide EV/S
for Nurix Therapeutics Inc.

Provide EV/GP
for Nurix Therapeutics Inc.

Provide EV/EBITDA
for Nurix Therapeutics Inc.

Provide EV/EBIT
for Nurix Therapeutics Inc.

Provide EV/OCF
for Nurix Therapeutics Inc.

Provide EV/FCFF
for Nurix Therapeutics Inc.

Provide EV/IC
for Nurix Therapeutics Inc.

Show me price targets
for Nurix Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Nurix Therapeutics Inc?

How accurate were the past Revenue estimates
for Nurix Therapeutics Inc?

What are the Net Income projections
for Nurix Therapeutics Inc?

How accurate were the past Net Income estimates
for Nurix Therapeutics Inc?

What are the EPS projections
for Nurix Therapeutics Inc?

How accurate were the past EPS estimates
for Nurix Therapeutics Inc?

What are the EBIT projections
for Nurix Therapeutics Inc?

How accurate were the past EBIT estimates
for Nurix Therapeutics Inc?

Compare the revenue forecasts
for Nurix Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Nurix Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Nurix Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Nurix Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Nurix Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Nurix Therapeutics Inc with its peers.

Analyze the financial leverage
of Nurix Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Nurix Therapeutics Inc.

Provide ROE
for Nurix Therapeutics Inc.

Provide ROA
for Nurix Therapeutics Inc.

Provide ROIC
for Nurix Therapeutics Inc.

Provide ROCE
for Nurix Therapeutics Inc.

Provide Gross Margin
for Nurix Therapeutics Inc.

Provide Operating Margin
for Nurix Therapeutics Inc.

Provide Net Margin
for Nurix Therapeutics Inc.

Provide FCF Margin
for Nurix Therapeutics Inc.

Show all solvency ratios
for Nurix Therapeutics Inc.

Provide D/E Ratio
for Nurix Therapeutics Inc.

Provide D/A Ratio
for Nurix Therapeutics Inc.

Provide Interest Coverage Ratio
for Nurix Therapeutics Inc.

Provide Altman Z-Score Ratio
for Nurix Therapeutics Inc.

Provide Quick Ratio
for Nurix Therapeutics Inc.

Provide Current Ratio
for Nurix Therapeutics Inc.

Provide Cash Ratio
for Nurix Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Nurix Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Nurix Therapeutics Inc?

What is the current Free Cash Flow
of Nurix Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Nurix Therapeutics Inc.

Financials

Balance Sheet Decomposition
Nurix Therapeutics Inc

Current Assets 251m
Cash & Short-Term Investments 244m
Other Current Assets 7m
Non-Current Assets 61.7m
Long-Term Investments 10.3m
PP&E 47.2m
Other Non-Current Assets 4.2m
Current Liabilities 87.6m
Accounts Payable 5.9m
Accrued Liabilities 35.6m
Other Current Liabilities 46.1m
Non-Current Liabilities 56.3m
Other Non-Current Liabilities 56.3m
Efficiency

Earnings Waterfall
Nurix Therapeutics Inc

Revenue
80.9m USD
Operating Expenses
-238.2m USD
Operating Income
-157.3m USD
Other Expenses
12.6m USD
Net Income
-144.7m USD

Free Cash Flow Analysis
Nurix Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

NRIX Profitability Score
Profitability Due Diligence

Nurix Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
Exceptional Revenue Growth Forecast
Declining ROE
24/100
Profitability
Score

Nurix Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

NRIX Solvency Score
Solvency Due Diligence

Nurix Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
54/100
Solvency
Score

Nurix Therapeutics Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NRIX Price Targets Summary
Nurix Therapeutics Inc

Wall Street analysts forecast NRIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NRIX is 25.09 USD with a low forecast of 14.14 USD and a high forecast of 36.75 USD.

Lowest
Price Target
14.14 USD
18% Upside
Average
Price Target
25.09 USD
109% Upside
Highest
Price Target
36.75 USD
206% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

NRIX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NRIX Price
Nurix Therapeutics Inc

1M 1M
-18%
6M 6M
+112%
1Y 1Y
+21%
3Y 3Y
-64%
5Y 5Y
-37%
10Y 10Y
-37%
Annual Price Range
12.02
52w Low
4.25
52w High
17.48
Price Metrics
Average Annual Return -0.35%
Standard Deviation of Annual Returns 67.78%
Max Drawdown -92%
Shares Statistics
Market Capitalization 659.9m USD
Shares Outstanding 54 903 400
Percentage of Shares Shorted 15.87%

NRIX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

659.9m USD

Dividend Yield

0%

Description

Nurix Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 242 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other challenging diseases. The company leverages its DELigase, an integrated discovery platform to identify and advance drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607, DeTIL-0255, KINASE-CTM3, COVID-CTMs, LIGASE-INH2 and DeCART. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. Its KINASE-CTM3, a kinase involved in T cell growth and activation to treat T cell malignancies and autoimmune disease.

Contact

CALIFORNIA
San Francisco
1700 Owens St Ste 205
+14156605320.0
https://www.nurixtx.com/

IPO

2020-07-24

Employees

242

Officers

CEO, President & Director
Dr. Arthur T. Sands M.D., Ph.D.
Chief Financial Officer
Mr. Johannes Van Houte
Chief Scientific Officer
Dr. Gwenn M. Hansen Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Arthur Weiss M.D., Ph.D.
Senior Accounting Manager
Rita Kwong
Chief Legal Officer, Secretary & Chief Compliance Officer
Dr. Christine Ring J.D., Ph.D.
Show More
Chief People Officer
Mr. Eric C. Schlezinger J.D.
Chief Business Officer
Dr. Jason Kantor Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one NRIX stock?

The intrinsic value of one NRIX stock under the Base Case scenario is 29.65 USD.

Is NRIX stock undervalued or overvalued?

Compared to the current market price of 12.02 USD, Nurix Therapeutics Inc is Undervalued by 59%.